Holen Sie sich die Stockscreener-App
24.38
2.31%
0.62
Schlusskurs vom Vortag:
$23.76
Offen:
$23.72
24-Stunden-Volumen:
286.94K
Relative Volume:
2.05
Marktkapitalisierung:
$798.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-12.33%
1M Leistung:
-0.21%
6M Leistung:
+24.73%
1J Leistung:
+0.00%
1-Tages-Spanne:
$22.74
$24.38
1-Wochen-Bereich:
$22.30
$29.26
52-Wochen-Spanne:
$14.35
$30.99
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $36.00 at HC Wainwright - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - Defense World
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com Canada
ArriVent BioPharma stock target raised on positive trial results By Investing.com - Investing.com Canada
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com UK
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - MarketBeat
Should investors be concerned about ArriVent BioPharma Inc. (AVBP)? - US Post News
Analyst boosts ArriVent BioPharma shares price target after promising trial data - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - MarketBeat
ArriVent reports promising data on lung cancer drug firmonertinib - Investing.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - ForexTV.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib - The Bakersfield Californian
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - StockTitan
ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher - MarketBeat
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance
ArriVent, lung cancer drug developer, files for $100M IPO - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4% - MarketBeat
ArriVent BioPharma Inc. Inc. (AVBP) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month High at $26.24 - MarketBeat
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - Quantisnow
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet - Yahoo Finance
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - Yahoo Canada Finance
Oppenheimer Reiterates Outperform Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
H.C. Wainwright ups ArriVent BioPharma shares target on clinical trial catalysts - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $30.00 at HC Wainwright - MarketBeat
HC Wainwright Boosts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $30.00 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Issues Quarterly Earnings Results - Defense World
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Given Outperform Rating at Oppenheimer - MarketBeat
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - wallstreet:online
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - Defense World
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - MarketBeat
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - StockTitan
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer - MyChesCo
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - StockTitan
(AVBP) Proactive Strategies - Stock Traders Daily
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Es liegen keine Finanzdaten für Arrivent Biopharma Inc (AVBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| GORDON CARL L | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| HEALY JAMES | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,696,752 |
1.28%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):